Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities:
Net loss	$ (14,263,830)	$ (16,738,815)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	11,137	2,440
Stock-based compensation	462,239	139,348
Non-cash operating lease cost	(29,121)	9,319
Acquisition-related IPR&D	(202,096)	507,000
Impairment of goodwill	0	5,187,519
Changes in operating assets and liabilities, net of impact of acquisition:
Other receivables	(201,423)	253,169
Prepaid expenses	(322,482)	(91,526)
Other current assets	0	193,495
Other non-current assets and deferred charges	237,937	145,223
Accounts payable	608,650	151,486
Accrued expenses	621,618	(27,083)
Deferred grant funding	(238,109)	0
Net cash used in operating activities	(13,315,480)	(10,268,425)
Investing activities:
Acquisition of Microchips cash	6,143,893	0
Purchases of property and equipment	0	(11,836)
Acquisition of Pear Tree and Hydra assets	0	(507,000)
Net cash provided by (used in) investing activities	6,143,893	(518,836)
Financing activities:
Net proceeds from issuance of common stock and warrants	5,151,702	10,111,952
Net cash provided by financing activities	5,151,702	10,111,952
Effect of exchange rate changes on cash and cash equivalents	(5,897)	(78,648)
Net change in cash and cash equivalents	(2,025,782)	(753,957)
Cash and cash equivalents, beginning of year	6,805,889	7,559,846
Cash and cash equivalents, end of year	4,780,107	6,805,889
Supplemental disclosure of non-cash operating, investing and financing activities:
Operating right-of-use assets obtained in exchange for new operating lease liabilities	583,697
Deemed dividend from trigger of down round provision	789,594	0
Microchips acquisition consideration paid in equity	$ 2,369,992	$ 0